“Many people in the field have seen the potential of the artificial pancreas systems and thought that they could add significant value”, Aaron Kowalski, vice president for research at JDRF, formerly the Juvenile Diabetes Research Foundation, which helped sponsor the study, told Reuters Health. But a study, published today in the New England Journal of Medicine, saw the technology safely provide three whole months of use, bringing us closer to the day when the wearable, smartphone-like device can be made available to patients.
Participants – who were not remotely monitored or supervised during the study – came from multiple sites and spent 12 weeks on the closed-loop system, then 12 weeks with standard insulin therapy.
Read Full Story